



# Phospho-RAF1 (S259) Recombinant Monoclonal Antibody

<b>Product Code</b>	CSB-RA019284A259phHU
<b>Abbreviation</b>	RAF proto-oncogene serine/threonine-protein kinase
<b>Storage</b>	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
<b>Uniprot No.</b>	P04049
<b>Immunogen</b>	A synthesized peptide derived from Human Phospho-RAF1 (S259)
<b>Species Reactivity</b>	Human
<b>Tested Applications</b>	ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200, IF:1:20-1:200
<b>Relevance</b>	<p>Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.</p>
<b>Form</b>	Liquid
<b>Conjugate</b>	Non-conjugated
<b>Storage Buffer</b>	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
<b>Purification Method</b>	Affinity-chromatography
<b>Isotype</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal



**Alias** RAF proto-oncogene serine/threonine-protein kinase, Proto-oncogene c-RAF, cRaf, Raf-1, RAF1, RAF


**Immunogen Species** Homo sapiens (Human)

**Research Area** Signal Transduction

**Gene Names** RAF1

**Clone No.** 4C9

## Image



### Western Blot


Positive WB detected in Hela whole cell lysate(treated with Calyculin A or EGF)

All lanes Phospho-RAF1 antibody at 1.18μg/ml  
Secondary


Goat polyclonal to rabbit IgG at 1/50000 dilution

Predicted band size: 73 KDa

Observed band size: 73 KDa



IHC image of CSB-RA019284A259phHU diluted at 1:100 and staining in paraffin-embedded human endometrial cancer performed on a Leica Bond<sup>TM</sup> system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4? overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.



Immunofluorescence staining of HepG2 cells with CSB-RA019284A259phHU at 1:100,counter-stained with DAPI. The cells were

fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4?. The secondary antibody was Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).

## Description

To create the phospho-RAF1 (S259) recombinant monoclonal antibody, the first step involves obtaining the genes responsible for coding this RAF1 antibody. These genes are sourced from rabbits previously exposed to a synthesized peptide derived from the human RAF1 protein phosphorylated at S259. Subsequently, these antibody genes are cloned into specialized expression vectors. Following this genetic modification, the vectors are carefully transfected into host suspension cells, which are then diligently cultivated to promote the expression and secretion of antibodies. The phospho-RAF1 (S259) recombinant monoclonal antibody is then subjected to a meticulous purification process using affinity chromatography, effectively separating the antibody from the surrounding



cell culture supernatant. Finally, the antibody's functionality is rigorously assessed through a battery of tests, including ELISA, WB, IHC, and IF, confirming its capability to effectively interact with the human RAF1 protein phosphorylated at S259.

Phosphorylation of RAF1 at S259 is a critical regulatory event in the MAPK signaling pathway, helping to control cell proliferation, differentiation, and survival. Dysregulation of this phosphorylation event can have significant implications for cancer and other diseases driven by abnormal signaling pathways.